Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.6.5, replacing the prior Revision: v3.6.4, indicating a small software update rather than any changes to the study details.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe site footer now displays Revision: v3.6.4, replacing the previous v3.6.3. This indicates a platform update with no changes to the study content.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a maintenance update to the page. There are no visible content or functionality changes indicated by the provided data.SummaryDifference0.0%

- Check44 days agoChange DetectedThe revision label on the page was updated from v3.6.0 to v3.6.2, signaling a recent update to the study details page.SummaryDifference0.0%

- Check58 days agoChange DetectedNew guidance sections were added to help users read the study record, answer common questions, and learn how to join, and the Intervention/Treatment label was updated. The recruitment status now shows 'No longer looking for participants', indicating enrollment has ended.SummaryDifference0.4%

- Check65 days agoChange DetectedRevision: v3.5.5 is now shown, replacing the previous v3.5.4. This indicates a minor update to the page content or structure without altering the underlying study information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.